Dr. Farshid Dayyani, MD, PhD

Dr. Dayyani practices at UCI Health - Orange in Orange, California, part of UC Irvine.

Dr. Dayyani's NPI, 1376710434, was assigned on May 8, 2008. Dr. Dayyani graduated from Ludwig Maximilian University of Munich Faculty of Medicine in 2002. Dr. Dayyani holds California license A125971.

Dr. Dayyani's primary practice is UCI Health - Orange, at 101 City Drive South, Orange, CA 92868 in Orange County. The practice phone is (714) 456-7890.

Dr. Dayyani's primary practice is UCI Health - Orange in Orange, California, part of UC Irvine. The medical group on file is UCI Health Physicians.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Dayyani practices. Vendor and product names are available with a free account.

Medical oncology is Dr. Dayyani's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Dayyani is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Dayyani's licenses on file in 4 states: California, Massachusetts, Arizona and Texas.

CMS data shows 766 Medicare services from Dr. Dayyani across 5 procedure codes in 2024, for 182 Medicare patients. Medicare paid $61,514 for them.

CMS counts 182 Medicare patients who saw Dr. Dayyani in 2024. The largest group is 65 to 74, with 102 patients. 75% of them have high blood pressure, and 72% have high cholesterol. 32% are also on Medicaid. Their average risk score is 2.47, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Dayyani's median patient age at 68, with 43% women.

In 2024, Dr. Dayyani wrote 604 Medicare Part D claims for 88 patients. 83% of them were for generic drugs. CMS names the drug for 392 of them, across 15 drugs with 11 or more claims each, at $320,679 in total drug cost. In 2023, CMS named 221 claims across 10 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Dayyani for performance year 2024, reported through an alternative payment model (APM). Dr. Dayyani accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Dayyani as offering telehealth.

Dmand AI links 93 papers to Dr. Dayyani, published from 2003 to 2025. 2024 was the busiest year, with 11. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Adenocarcinoma and Biomarkers, Tumor. Dr. Dayyani has published most often in Cancers (Basel). Dr. Dayyani's most frequent co-authors are Maheswari Senthil, MD, May T. Cho, MD and Jennifer Brooke Valerin, MD.

Dmand AI links Dr. Dayyani to 2 clinical trials. 1 is still active or recruiting. Conditions studied include Carcinoma, Hepatocellular and Liver Neoplasms.

CMS Open Payments shows 1,194 general payments to Dr. Dayyani from 28 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 67% of the total. Sirtex Medical Inc paid the most, $276,290. It also lists 8 research payments totaling $8,799 from 2018 to 2022.

Dr. Dayyani graduated from Ludwig Maximilian University of Munich Faculty of Medicine in 2002. Dr. Dayyani is a member of ASCO.

Dr. Dayyani is in network with 13 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.